Amulet Capital Partners

Amulet Capital Partners is a middle-market private equity firm exclusively focused on the healthcare sector, investing in high-potential opportunities across subsectors such as life sciences outsourcing, healthcare providers, and payor/payor services. The firm deploys a disciplined strategy involving thematic sourcing based on emerging trends, tailored capital solutions that address operational and regulatory complexities, and hands-on value creation supported by a network of healthcare operators and experts. With investments typically ranging from $25 to $200 million, Amulet partners closely with management teams to drive strategic growth, programmatic M&A, and long-term value creation, aiming to build enduring market leaders.

Founded in 2015 in Greenwich, Connecticut, Amulet Capital Partners was established on a thesis of deep sector expertise and long-term partnerships in healthcare. The firm has grown significantly over its first decade, raising three funds: Fund I at $288 million in 2016, Fund II at $650 million, and Fund III at $1.2 billion. Key milestones include opening a California office in Walnut Creek, forming a Portfolio Resource Group for operational support, and achieving multiple exits, demonstrating its ability to navigate complex markets and deliver results across cycles.

Amulet’s portfolio features notable platform investments and add-ons, including Assembled Intelligence (life sciences communications), US Fertility (reproductive care), Theoria Medical, U.S. Digestive Health, United Vein & Vascular Centers, Lighthouse Behavioral Health Solutions, Unlock Health, Alliance Clinical Network, Genetics & IVF Institute, and past holdings like OPEN Health and SSI Strategy. The firm has completed 14 platform investments and 38 add-on acquisitions as of late 2025, with recent activity including the sale of SSI Strategy to Clinigen and a strategic partnership for US Fertility with L Catterton. These investments highlight Amulet’s focus on scalable platforms in dynamic healthcare segments.

The team comprises experienced partners, investment professionals, and operators with deep healthcare backgrounds, including Partners such as Nick Amigone, Avi Uttamchandani, Carl Zimmerman, and Michael Keaveney (Head of Investor Relations). Supported by principals, vice presidents, and a dedicated Portfolio Resource Group, the group emphasizes collaboration, rigorous analysis, and operational insight to execute strategies and steward portfolio companies toward premium valuations.